Company
TSE:NUMI
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
74 stories · page 3 of 4
The company said the license expansion will further position it as a recognized global research centre for natural psychedelic medicines
The new bioscience advisory board will contribute strategically to advancing Numinus' IP strategy, including product development and clinical trial activities out of the company's Health Canada-licensed research facility
Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin
The mental healthcare company saw its revenue grow by 245% to $0.8 million during the three-month period ended November 30, 2021
Numinus will host the Canadian sites for MAPPUSX, managed through its two recently acquired, purpose-designed clinics, allowing for quick completion of the Canadian segment of the MAPS-sponsored trial.
The formulation has been developed to stably deliver psilocybin and other synergistic compounds and will be studied for safety and bioavailability on 20 healthy volunteers, followed by testing against a comparator on 28 more volunteers
The policy amendment allows Canadian physicians to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis
"During the fourth quarter we were focused on building the team, infrastructure, technologies and protocols that will allow us to scale our business over the next several years," founder and CEO Payton Nyquvest said
"The testing we've developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and ultimately the industry," said the company's science
Upon moving up from the TSX Venture Exchange , the company's shares will continue to trade under the symbol NUMI
Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms
“We look forward to deepening our collaboration with MAPS while expanding the resources and solutions available to those suffering from PTSD," said Numinus CEO Payton Nyquvest
The company said the finalized study design and protocol mark a major milestone to investigate natural psilocybin
The expanded lab will double the size of the company's research footprint and is slated for completion in the summer of 2022
NCT will operate as the "Neurology Centre of Toronto by Numinus" and continue under the leadership of its founder, Dr Evan Lewis
For the period ended May 31, 2021, the health care company saw revenue of $562,076, up 160% from $216,244 in the same quarter of 2020
Approval at the federal level means that Numinus can now transition the study into the final stages of training staff, sourcing medication and recruit patients
Numinus said that it plans to expand NCT into a “comprehensive clinical neurology treatment centre” that specializes in psychedelic treatment for neurological disorders
The company said that its proprietary process “dramatically” increases the production of psychoactive fungi species that contain psilocybin
Numinus told shareholders that the new team will support its aim to expand its clinic network internationally, develop and market psychedelic-assisted psychotherapies and boost laboratory capabilities
